Kevin Smith - Inogen General Development
| INGN Stock | USD 9.38 0.17 1.85% |
Executive
Kevin Smith is General Development of Inogen Inc
| Age | 53 |
| Address | 859 Ward Drive, Goleta, CA, United States, 93111 |
| Phone | 805 562 0500 |
| Web | https://www.inogen.com |
Kevin Smith Latest Insider Activity
Tracking and analyzing the buying and selling activities of Kevin Smith against Inogen stock is an integral part of due diligence when investing in Inogen. Kevin Smith insider activity provides valuable insight into whether Inogen is net buyers or sellers over its current business cycle. Note, Inogen insiders must abide by specific rules, including filing SEC forms every time they buy or sell Inogen'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Kevin Smith over two months ago Acquisition by Kevin Smith of 687 shares of CNA Financial subject to Rule 16b-3 | ||
Kevin Smith over three months ago Insider Trading |
Inogen Management Efficiency
The company has return on total asset (ROA) of (0.0966) % which means that it has lost $0.0966 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2533) %, meaning that it created substantial loss on money invested by shareholders. Inogen's management efficiency ratios could be used to measure how well Inogen manages its routine affairs as well as how well it operates its assets and liabilities. As of the 25th of November 2024, Return On Tangible Assets is likely to grow to -0.35. In addition to that, Return On Capital Employed is likely to grow to -0.41. At this time, Inogen's Deferred Long Term Asset Charges is very stable compared to the past year. As of the 25th of November 2024, Intangibles To Total Assets is likely to grow to 0.14, while Total Assets are likely to drop about 292 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Paul Pignato | CVRx Inc | N/A | |
| Jonelle Burnham | CVRx Inc | 53 | |
| Lucas Vitale | Orthofix Medical | 47 | |
| Dylan John | Neuropace | N/A | |
| Aimee Einstein | Si Bone | N/A | |
| Reay MD | Sight Sciences | N/A | |
| Julie Andrews | Orthofix Medical | 53 | |
| Marshall MD | Artivion | 67 | |
| Nikolas Kerr | Si Bone | 52 | |
| Robert John | CVRx Inc | N/A | |
| Gordon Weber | SurModics | 61 | |
| Kelley Nicholas | Neuropace | N/A | |
| Anthony Recupero | Si Bone | 65 | |
| Mehul Joshi | Pulmonx Corp | 63 | |
| Teryl Sides | SurModics | 54 | |
| Jennifer Englund | CVRx Inc | N/A | |
| Julie Dewey | Orthofix Medical | 63 | |
| Sarah Huber | Pulmonx Corp | N/A | |
| Jeff Bertolini | Si Bone | N/A | |
| Sarah Oliker | CONMED | 43 | |
| MSc MD | CVRx Inc | N/A | |
Management Performance
| Return On Equity | -0.25 | ||||
| Return On Asset | -0.0966 |
Inogen Inc Leadership Team
Elected by the shareholders, the Inogen's board of directors comprises two types of representatives: Inogen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Inogen. The board's role is to monitor Inogen's management team and ensure that shareholders' interests are well served. Inogen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Inogen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Bourque, CFO VP | ||
| Nabil Shabshab, Pres CEO | ||
| Vijay Paliwal, Senior Enablement | ||
| Adrien Mithalal, Senior Development | ||
| Bart Sanford, Executive Vice President Operations | ||
| Agnes Lee, VP Planning | ||
| Philip Corrin, Senior Chain | ||
| Michael Sergesketter, Chief President | ||
| Jason Somer, General VP | ||
| Jennifer Boyer, Executive Officer | ||
| Krishna Jhaveri, Chief Officer | ||
| Kevin Smith, General Development | ||
| Michael CPA, CFO VP | ||
| MBA MD, Executive Officer | ||
| George Parr, Ex Officer | ||
| Matthew Pigeon, Investor Officer | ||
| Kristin Caltrider, CFO VP | ||
| Grgoire Ramade, Executive Officer | ||
| Alison Bauerlein, Co-Founder, CFO, Principal Accounting Officer, Executive VP of Fin., Treasurer and Secretary | ||
| Paul Andreassi, Senior Affairs |
Inogen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Inogen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.25 | ||||
| Return On Asset | -0.0966 | ||||
| Profit Margin | (0.16) % | ||||
| Operating Margin | (0.08) % | ||||
| Current Valuation | 122.9 M | ||||
| Shares Outstanding | 23.82 M | ||||
| Shares Owned By Insiders | 1.78 % | ||||
| Shares Owned By Institutions | 90.10 % | ||||
| Number Of Shares Shorted | 826.34 K | ||||
| Price To Earning | 61.63 X |
Pair Trading with Inogen
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Inogen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Inogen will appreciate offsetting losses from the drop in the long position's value.Moving against Inogen Stock
| 0.63 | VMD | Viemed Healthcare | PairCorr |
| 0.41 | DOCS | Doximity | PairCorr |
| 0.37 | FIGS | Figs Inc | PairCorr |
| 0.37 | CVS | CVS Health Corp Aggressive Push | PairCorr |
| 0.36 | SSY | SunLink Health Systems | PairCorr |
The ability to find closely correlated positions to Inogen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Inogen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Inogen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Inogen Inc to buy it.
The correlation of Inogen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Inogen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Inogen Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Inogen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inogen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inogen. If investors know Inogen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inogen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.873 | Earnings Share (2.25) | Revenue Per Share 14.095 | Quarterly Revenue Growth 0.058 | Return On Assets (0.1) |
The market value of Inogen Inc is measured differently than its book value, which is the value of Inogen that is recorded on the company's balance sheet. Investors also form their own opinion of Inogen's value that differs from its market value or its book value, called intrinsic value, which is Inogen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inogen's market value can be influenced by many factors that don't directly affect Inogen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inogen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Inogen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inogen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.